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ADDITIONAL COMMENTS TO THE ARTICLE WRITTEN BY EYMARD
TORRES-RODRIGUEZ ET AL: REDUCTION OF CARDIOVASCULAR RISK IN
OBESE PATIENTS WHO PARTICIPATED IN A LIFESTYLE MEDICINE PROGRAM
COMENTARIOS SOBRE EL ARTÍCULO: “DISMINUCIÓN DEL RIESGO CARDIOVASCULAR EN PACIENTES
OBESOS QUE PARTICIPARON EN UN PROGRAMA DE MEDICINA DE ESTILO DE VIDA”
John C. Longa López 1,a

Dear Editor
Chronic diseases have occupied a leading place in global morbidity and mortality statistics, given the
increase in life expectancy and access to new therapeutic technologies and advanced drugs. Cardiometabolic diseases such as diabetes, high blood pressure, dyslipidemia, and obesity, among others, are clear
examples of both the impact and the advent of new therapeutic opportunities. In this study, the eﬀect of a
lifestyle program on the cardiovascular risk of enrolled patients was evaluated.
However, it is essential to point out that the sample size included (n= 9) is small to be able to reach
generalizations in such a short time, especially in an impact variable that is calculated in the long term (10
years) in the outcome of events " hard” such as cardiovascular events (fatal and non-fatal myocardial infarction
or cerebrovascular accident) and especially having a “complacent” starting point in which 77.8% of patients
already came with low cardiovascular risk. Not having a group control, being themselves their control, and
not having the statistical signi cance of the changes observed in the variables studied, is a signi cant
limitation to attribute the results obtained to the program in question.
In the present study, it is noteworthy that patients with stage 3 and 2 arterial hypertension, for example,
apparently passed to lower stages. Still, it is not mentioned whether they received pharmacological
treatment, which was mandatory in this degree of arterial hypertension, given its magnitude. : if he did not
receive it, it was a regrettable omission, and if he did receive it, then the pharmacological control was not
adequate, and we cannot attribute the drop in blood pressure only to the lifestyle program. Another aspect
that draws a lot of attention is the decrease in the reported body mass index, in which there is a decrease in the
percentage of fat but especially in muscle mass, which constitutes an "unwanted" outcome that could lead to
what we call sarcopenic obesity, with the dire consequences in cardiovascular risk that have the loss of muscle
mass. An important limitation is the fact that patients are not given basal glucose, a variable with a high
impact on cardiovascular risk since, being obese, it was necessary to rule out diabetes in this group to better
stratify it.
The present author has allowed himself to do an exercise to assess long-term cardiovascular risk with the
changes achieved by the program cited in this study to see the impact of this intervention on cardiovascular
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mortality over more than 10 years, using the QRISK
Lifetime Cardiovascular Risk Calculator and using the
mean values of the entire group (n=9) obtained after 6
months of intervention reported in the tables presented.
Thus, a patient with an average age of 51 years (reported
in the study), a non-smoker (since none of the group was
a smoker), with a total/HDL cholesterol ratio of 5.27 and
4.98, before and after the intervention (the average LDLC reported by the study and an average valuemg/dl

of 40 of HDL-C before and after the intervention have
been considered, the latter parameter that was not
evaluated in the present study and that constitutes a
limiting) with a systolic pressure of 132 and 124 mmHg
(before and after the intervention, respectively, values
reported by the study) and a weight of 109 and 106 kg
(before and after the intervention reported by the study)
have the following curves projection of cardiovascular
risk: 44.3 41.2.

Figure 1. Change in cardiovascular risk estimated with QRISK Lifetime
Cardiovascular Risk Calculator
Note that the cardiovascular risk curves only begin to
separate above 60 years of age, which tells us about the
need for long-term sustainability of interventions to
really have a signi cant impact.

Finally, there is no doubt that changes in lifestyle are a
fundamental pillar for the prevention of many chronic
diseases and that cardiovascular risk strati cation allows
the pro ling of each patient towards the practice of
individualized medicine with a preventive approach.
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